Recent genomic advances have exacerbated the problem of interpreting genome-wide association studies aimed at uncovering genetic basis of brain disorders. Despite of a plethora of data on candidate genes determining the susceptibility to neuropsychiatric diseases, no consensus is reached on their intrinsic contribution to the pathogenesis, and the influence of the environment on these genes is incompletely understood. Alternatively, single-cell analyses of the normal and diseased human brain have shown that somatic genome/epigenome variations (somatic mosaicism) do affect neuronal cell populations and are likely to mediate pathogenic processes associated with brain dysfunctions. Such (epi-)genomic changes are likely to arise from disturbances in genome maintenance and cell cycle regulation pathways as well as from environmental exposures. Therefore, one can suggest that, at least in a proportion of cases, inter- and intragenic variations (copy number variations (CNVs) or single nucleotide polymorphisms (SNPs)) associated with major brain disorders (i.e. schizophrenia, Alzheimer's disease, autism) lead to genetic dysregulation resulting in somatic genetic and epigenetic mosaicism. In addition, environmental influences on malfunctioning cellular machinery could trigger a cascade of abnormal processes producing genomic/chromosomal instability (i.e. brain-specific aneuploidy). Here, a brief analysis of a genome-wide association database has allowed us to support these speculations. Accordingly, an ontogenetic 2-/multiple-hit mechanism of brain diseases was hypothesized. Finally, we speculate that somatic cell genomics approach considering both genome-wide associations and somatic (epi-)genomic variations is likely to have bright perspectives for disease-oriented genome research.

Keywords:
Brain disorders, Genome-wide association hypothesis, Mosaicism-genetic-environmental interactions, Somatic genome variations
1.
Anney R, Klei L, Pinto D, Regan R, Conroy J, et al: A genome-wide scan for common alleles affecting risk for autism. Hum Mol Genet 19:4072-4082 (2010).
2.
Arendt T, Bruckner MK, Mosch B, Losche A: Selective cell death of hyperploids neurons in Alzheimer's disease. Am J Pathol 177:15-20 (2010).
3.
Borysov SI, Granic A, Padmanabhan J, Walczak CE, Potter H: Alzheimer Aβ disrupts the mitotic spindle and directly inhibits mitotic microtubule motors. Cell Cycle 10:1397-1410 (2011).
4.
Chan WY, Lorke DE, Tiu SC, Yew DT: Proliferation and apoptosis in the developing human neocortex. Anat Rec 267:261-276 (2002).
5.
Celestino-Soper PB, Skinner C, Schroer R, Eng P, Shenai J, et al: Deletions in chromosome 6p22.3-p24.3, including ATXN1, are associated with developmental delay and autism spectrum disorders. Mol Cytogenet 5:17 (2012).
6.
Chow ML, Pramparo T, Winn ME, Barnes CC, Li HR, et al: Age-dependent brain gene expression and copy number anomalies in autism suggest distinct pathological processes at young versus mature ages. PLoS Genet 8:e1002592 (2012).
7.
de Graaf-Peters VB, Hadders-Algra M: Ontogeny of the human central nervous system: what is happening when? Early Hum Dev 82:257-266 (2006).
8.
Geller LN, Potter H: Chromosome missegregation and trisomy 21 mosaicism in Alzheimer's disease. Neurobiol Dis 6:167-179 (1999).
9.
Geschwind DH, Konopka G: Neuroscience in the era of functional genomics and systems biology. Nature 461:908-915 (2009).
10.
Ginsberg SD, Elarova I, Ruben M, Tan F, Counts SE, et al: Single-cell gene expression analysis: implications for neurodegenerative and neuropsychiatric disorders. Neurochem Res 29:1053-1064 (2004).
11.
Girirajan S, Eichler EE: Phenotypic variability and genetic susceptibility to genomic disorders. Hum Mol Genet 19:R176-R187 (2010).
12.
Granic A, Padmanabhan J, Norden M, Potter H: Alzheimer Abeta peptide induces chromosome mis-segregation and aneuploidy, including trisomy 21: requirement for tau and APP. Mol Biol Cell 21:511-520 (2010).
13.
Heng HH, Liu G, Stevens JB, Bremer SW, Ye KJ, et al: Decoding the genome beyond sequencing: the new phase of genomic research. Genomics 98:242-252 (2011).
14.
Herrup K, Yang Y: Cell cycle regulation in the postmitotic neuron: oxymoron or new biology? Nat Rev Neurosci 8:368-378 (2007).
15.
Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, et al: Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci USA 106:9362-9367 (2009).
16.
Hochstenbach R, Buizer-Voskamp JE, Vorstman JA, Ophoff RA: Genome arrays for the detection of copy number variations in idiopathic mental retardation, idiopathic generalized epilepsy and neuropsychiatric disorders: lessons for diagnostic workflow and research. Cytogenet Genome Res 135:174-202 (2011).
17.
Iourov IY, Liehr T, Vorsanova SG, Kolotii AD, Yurov YB: Visualization of interphase chromosomes in postmitotic cells of the human brain by multicolour banding (MCB). Chromosome Res 14:223-229 (2006a).
18.
Iourov IY, Vorsanova SG, Yurov YB: Chromosomal variation in mammalian neuronal cells: known facts and attractive hypotheses. Int Rev Cytol 249:143-191 (2006b).
19.
Iourov IY, Vorsanova SG, Yurov YB: Chromosomal mosaicism goes global. Mol Cytogenet 1:26 (2008a).
20.
Iourov IY, Vorsanova SG, Yurov YB: Molecular cytogenetics and cytogenomics of brain diseases. Curr Genomics: 452-465 (2008b).
21.
Iourov IY, Vorsanova SG, Liehr T, Kolotii AD, Yurov YB: Increased chromosome instability dramatically disrupts neural genome integrity and mediates cerebellar degeneration in the ataxia-telangiectasia brain. Hum Mol Genet 18:2656-2669 (2009a).
22.
Iourov IY, Vorsanova SG, Liehr T, Yurov YB: Aneuploidy in the normal, Alzheimer's disease and ataxia-telangiectasia brain: differential expression and pathological meaning. Neurobiol Dis 34:212-220 (2009b).
23.
Iourov IY, Vorsanova SG, Yurov YB: Somatic genome variations in health and disease. Curr Genomics. 11:387-396 (2010).
24.
Iourov IY, Vorsanova SG, Yurov YB: Genomic landscape of the Alzheimer's disease brain: chromosome instability - aneuploidy, but not tetraploidy - mediates neurodegeneration. Neurodegener Dis 8:35-37 (2011).
25.
Kingsbury MA, Yung YC, Peterson SE, Westra JW, Chun J: Aneuploidy in the normal and diseased brain. Cell Mol Life Sci 63:2626-2641 (2006).
26.
Leblond CS, Heinrich J, Delorme R, Proepper C, Betancur C, et al: Genetic and functional analyses of SHANK2 mutations suggest a multiple hit model of autism spectrum disorders. PLoS Genet 8:e1002521 (2012).
27.
Mosch B, Morawski M, Mittag A, Lenz D, Tarnok A, Arendt T: Aneuploidy and DNA replication in the normal human brain and Alzheimer's disease. J Neurosci 27:6859-6867 (2007).
28.
Pearson TA, Manolio TA: How to interpret a genome-wide association study. JAMA 299:1335-1344 (2008).
29.
Poot M, van der Smagt JJ, Brilstra EH, Bourgeron T: Disentangling the myriad genomics of complex disorders, specifically focusing on autism, epilepsy, and schizophrenia. Cytogenet Genome Res 135:228-240 (2011).
30.
Visscher PM, Brown MA, McCarthy MI, Yang J: Five years of GWAS discovery. Am J Hum Genet 90:7-24 (2012).
31.
Voineagu I: Gene expression studies in autism: moving from the genome to the transcriptome and beyond. Neurobiol Dis 45:69-75 (2012).
32.
Vorsanova SG, Voinova VIu, Iurov IIu, Kurinnaia OS, Demidova IA, Iurov IuB: Cytogenetic, molecular cytogenetic, clinical and genealogical study of mothers of children with autism: a search for family genetic markers of autistic disorders. Zh Nevrol Psikhiatr Im S S Korsakova 109:54-64 (2009).
33.
Vorsanova SG, Yurov YB, Iourov IY: Human interphase chromosomes: a review of available molecular cytogenetic technologies. Mol Cytogenet 3:1 (2010).
34.
Wang W, Bu B, Xie M, Zhang M, Yu Z, Tao D: Neural cell cycle dysregulation and central nervous system diseases. Prog Neurobiol 89:1-17 (2009).
35.
Westra JW, Peterson SE, Yung YC, Mutoh T, Barral S, Chun J: Aneuploid mosaicism in the developing and adult cerebellar cortex. J Comp Neurol 507:1944-1951 (2008).
36.
Westra JW, Barral S, Chun J: A reevaluation of tetraploidy in the Alzheimer's disease brain. Neurodegener Dis 6:221-229 (2009).
37.
Westra JW, Rivera RR, Bushman DM, Yung YC, Peterson SE, et al: Neuronal DNA content variation (DCV) with regional and individual differences in the human brain. J Comp Neurol 518:3981-4000 (2010).
38.
Wu C, Orozco C, Boyer J, Leglise M, Goodale J, et al: BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol 10:R130 (2009).
39.
Yang Y, Geldmacher DS, Herrup K: DNA replication precedes neuronal cell death in Alzheimer's disease. J Neurosci 21:2661-2668 (2001).
40.
Yurov YB, Vostrikov VM, Vorsanova SG, Monakhov VV, Iourov IY: Multicolor fluorescent in situ hybridization on post-mortem brain in schizophrenia as an approach for identification of low-level chromosomal aneuploidy in neuropsychiatric diseases. Brain Dev 23:S186-190 (2001).
41.
Yurov YB, Iourov IY, Monakhov VV, Soloviev IV, Vostrikov VM, Vorsanova SG: The variation of aneuploidy frequency in the developing and adult human brain revealed by an interphase FISH study. J Histochem Cytochem 53:385-390 (2005).
42.
Yurov YB, Iourov IY, Vorsanova SG, Liehr T, Kolotii AD, et al: Aneuploidy and confined chromosomal mosaicism in the developing human brain. PLoS One 2:e558 (2007a).
43.
Yurov YB, Vorsanova SG, Iourov IY, Demidova IA, Beresheva AK, et al: Unexplained autism is frequently associated with low-level mosaic aneuploidy. J Med Genet 44: 521-525 (2007b).
44.
Yurov YB, Iourov IY, Vorsanova SG, Demidova IA, Kravetz VS, et al: The schizophrenia brain exhibits low-level aneuploidy involving chromosome 1. Schizophr Res 98: 139-147 (2008).
45.
Yurov YB, Vorsanova SG, Iourov IY: GIN'n'CIN hypothesis of brain aging: deciphering the role of somatic genetic instabilities and neural aneuploidy during ontogeny. Mol Cytogenet 2:23 (2009).
46.
Yurov YB, Vorsanova SG, Iourov IY: Ontogenetic variation of the human genome. Curr Genomics 11:420-425 (2010).
47.
Yurov YB, Vorsanova SG, Iourov IY: The DNA replication stress hypothesis of Alzheimer's disease. ScientificWorldJournal 11:2602-2612 (2011).
48.
Zhu X, Raina AK, Perry G, Smith MA: Alzheimer's disease: the two-hit hypothesis. Lancet Neurol 3:219-226 (2004).
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.